AFME.PA

Affluent Medical SA [AFME.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

AFME.PA Stock Summary

Top 10 Correlated ETFs

AFME.PA

Top 10 Correlated Stocks

AFME.PA

In the News

AFME.PA Financial details

Company Rating
-
Market Cap
65.96M
Income
-22.52M
Revenue
1.22M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
52
Optionable
No
Shortable
Yes
Earnings
28 Sep 2023
P/E
-2.11
Forward P/E
-
PEG
-5.63
P/S
-
P/B
0.95
P/C
-
P/FCF
-4.68
Quick Ratio
0.3
Current Ratio
0.83
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.83
EPS next Y
-
EPS next Q
-
EPS this Y
1.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
2.38%
Revenue last 5Y
98.91%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-3.6%
SMA50
-2.19%
SMA100
-7.59%
Inst Own
-
Inst Trans
-
ROA
-25%
ROE
-39%
ROC
-0.28%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.93-2.3
52W High
-
52W Low
-
RSI
44.28
Rel Volume
0.12
Avg Volume
10.9K
Volume
1.3K
Perf Week
-2.22%
Perf Month
-4.35%
Perf Quarter
-27.47%
Perf Half Y
-21.89%
-
-
-
-
Beta
0.501
-
-
Volatility
0.02%, 0.04%
Prev Close
-1.49%
Price
1.32
Change
0%

Something similar

Top by Market Cap
MSF.DE
MSFT
META
EMBASSY.NS
JPM
Top Correlated ETFs
LGQI.DE
EHF1.DE
XU61.DE
ISFA.AS
100H.PA
Top Correlated Stocks
0IJV.L
VODI.DE
0IW3.L
0IVQ.L
NOVN.SW
Similar Market Cap
FLCH
PSTI
BEST
ARB.L
1194.HK

Company Profile

Healthcare Medical - Devices
  • Volume Average 10.9K
  • Market Capitalization 65.96M
  • Employee 52
  • CEO Sebastien Ladet Ph.D.
  • Headquarters Aix-en-Provence,FR
  • IPO Date 2021-06-14
  • Website https://www.affluentmedical.com

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.